Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 600511.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 600511.SS and 80,000+ other tickers.
See exactly how 600511.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 600511.SS and 80,000+ other tickers.
China National Medicines Corporation Ltd., in conjunction with its various operating entities, is a prominent player in the distribution of pharmaceutical goods across China. The enterprise's scope extends to the production and commercialization of innovative as well as pre-existing drug formulations. Additionally, it markets both traditional Chinese patent remedies and modern Western medications, alongside a range of medical apparatus. Complementing these activities, the firm delivers warehousing solutions and acts as an agent for import and export transactions. Its diverse clientele…
No recent news available.